Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

BMC Gastroenterology

Table 2 **Univariate analyses of factors by cox regression model associated with recurrence-free survival (RFS) in test and validation cohort (*, P < 0.05; , P < 0.01)

	Test cohort		Validation cohort
Variable	RFS hazard ratio (95% Cl)	Pvalue	RFS hazard ratio (95% Cl)	Pvalue
Age (≤50, > 50)	0.463 (0.178-1.206)	0.115	3.673 (1.126-11.983)	0.031*
Gender (male, female)	0.594 (0.237-1.489)	0.266	0.342 (0.161-0.728)	0.005**
Tumor site (stomach, no stomach)	9.629 (2.820-32.879)	<0.001**	1.760 (0.900-3.440)	0.098
Tumor size (≤10, > 10 cm)	8.732 (3.604-21.154)	<0.001**	5.392 (2.787-10.430)	<0.001**
Mitosis count (≤10, > 10/50 HPF)	13.459 (5.470-33.115)	<0.001**	8.462 (4.335-16.519)	<0.001**
Serosal invasion (Yes, No)	20.531 (8.170-51.596)	<0.001**	7.706 (3.938-15.081)	<0.001**